Titlebook: Entry Inhibitors in HIV Therapy; Jacqueline D. Reeves,Cynthia A. Derdeyn Book 2007 Birkhäuser Basel 2007 AIDS.HIV.HIV Therapy.HIV infectio

enamel

书目名称Entry Inhibitors in HIV Therapy影响因子(影响力)




书目名称Entry Inhibitors in HIV Therapy影响因子(影响力)学科排名




书目名称Entry Inhibitors in HIV Therapy网络公开度




书目名称Entry Inhibitors in HIV Therapy网络公开度学科排名




书目名称Entry Inhibitors in HIV Therapy被引频次




书目名称Entry Inhibitors in HIV Therapy被引频次学科排名




书目名称Entry Inhibitors in HIV Therapy年度引用




书目名称Entry Inhibitors in HIV Therapy年度引用学科排名




书目名称Entry Inhibitors in HIV Therapy读者反馈




书目名称Entry Inhibitors in HIV Therapy读者反馈学科排名

BLOT

时代

墙壁

CREEK

Inhibitors that target gp120 interactions with coreceptor,ssays on human cell lines as syncytium inducing (SI) or non-syncytium inducing (NSI) [.]. NSI viruses predominate early after transmission, are capable of growth in primary macrophages (macrophage tropism), and fail to grow in most established human T cell lines. SI viruses, by contrast, are found i

半球

半球

Entry inhibition of HIV-1 subtype C isolates, [.]. There is less information on how genetic variability might affect the efficacy of a newer class of anti-retrovirals, the entry or fusion inhibitors. This group comprises a diverse collection of compounds that target both viral and host cell components blocking virus attachment and/or fusion an

PACK

重画只能放弃

Future clinical prospects for entry inhibitors,once (with the FDA approval of a membrane fusion inhibitor, enfuvirtide, in 2003) has this strategic approach resulted in a commercially available agent. Indeed, for more than 15 years, from 1987 to 2003, all available antiretroviral therapies targeted one of two HW-encoded enzymes, reverse transcri

Obsessed